(FHD). Among 60 FHD patients from 27 families with two or more cases per family, we tested available paraffinized tumor tissues from 46 cases by in situ hybridization for EBVencoded RNA (EBERI) expression. Thirteen of 46 FHD patients (28%) had EBERI expressed in the Reed-Sternberg cells. Concordance rate of EBV positivity was evaluated among 34 first-degree related pairs from 17 families for which both cases had available paraffinized tumor tissues. Only two of 17 pairs were concordant for EBERI positivity. There was no excess of positive concordance ( P = .18). Serologically, FHD patients had higher geometric mean antibody AMILIAL HODGKIN'S DISEASE (FHD) is a welldefined entity.' As with sporadic Hodgkin's disease (HD), the causes are still unclear. Most investigations of FHD have explored the association of HLA phenotype and disease susceptibility.' However, it is likely that only a subset of the FHD cases are due to an HLA-linked susceptibility gene.3 Little is known about the environmental risk factors for FHD.4
titers (GMTs) to the viral capsid antigen (VCA) and early antigen D (EA-D)
. There was no difference in seroprevalence between patients and control groups, nor was there concordance in elevated serology among 15 pairs of first-degree related FHD cases. Young adult unaffected family members (UFM) may not react to EBV in the same way as the general population as evidenced by the lower titer of VCA, although not statistically significant, and significantly lower titers of EA-D, compared with age-matched controls. While EBV might have some role in a subset of HD, lack of concordance of EBERI expression and EBV serology among the FHD cases in the same family suggest that EBV does not play an important role in FHD. 0 1996 by The American Society of Hematology.
cell^."^ Taken together, these data have made EBV a leading etiologic candidate for HD." If a shared exposure were important in developing FHD, EBV would also be a likely candidate.
Our main objective was to elucidate the role of EBV in a cohort of FHD. We undertook EBV in situ hybridization and serologic studies to determine whether there was concordance among FHD patients, either in the presence of EBVcarrying tumors or in abnormal serology.
MATERIALS AND METHODS
Study population. FHD is defined as two or more cases of HD in the same family. We identified 60 cases from 27 such families, in which at least one case per family had available paraffinized tumor tissue for EBV in situ hybridization. Kindreds were accrued to the Genetic Epidemiology Branch of the National Cancer Institute from 1971 to 1992. Some families were identified when a family member was treated for HD at the Clinical Center of National Institutes of Health, some were referred by physicians, and some were self-referred. The diagnoses of HD were confirmed by histologic review of available specimens by the study pathologist (E.S.J.) (n = 46), review of original pathology reports or medical records if histologic material was no longer available (n = 12), or review of death certificates if medical records were no longer available (n = 2). After giving informed consent, all subjects with HD who were available for study completed a questionnaire to obtain medical and family history. Most of the participants had a routine physical examination and a blood sample collected for etiologic investigation, including EBV serology. Paraffin-embedded specimens were sectioned for in situ hybridization, as described later.
Control populations. All available first-degree unaffected family members (UFM) of each family member with HD, such as siblings or parents, were studied for EBV serology. In addition, two sex-and age-matched (within the same decade or 5-year difference) healthy controls from a previously described, population-based survey' ' were matched to FHD cases and to UFM.
In siru hybridization. The procedure has been described previously in detail." Briefly, 5-pm sections of paraffin-embedded tissue were prepared on silanated slides. The sections were deparaffinized, rehydrated, permeabilized with a nonionic detergent, and digested with proteinase K (IO pg/mL). The riboprobe was applied in a formamide buffer, and the slides were hybridized overnight. Following stringent posthybridization washes, an antidigoxigenin alkaline phosphatase antibody conjugate was applied to each slide. The slides were then washed and placed into a color-developing solution that consisted of nitrobluetetrazolium and X-phosphate. The reaction was stopped by briefly washing the slides in an appropriate buffer. The slides were counterstained with eosin. The integrity of the RNA in each tissue section was evaluated with a digoxigeninlabeled riboprobe (105 bp) directed at an abundant cellular mRNA transcript for a small nuclear ribonucleoprotein, snRNP U6." Sections that showed hybridization signal with the U6 probe were determined adequate for analysis with the EBERl probe. A positive control slide, prepared from a paraffin-embedded tissue block that contained metastatic nasopharyngeal carcinoma to lymph node, was included in each hybridization run.
EBVserology. Immunoglobulin G (IgG) antiviral capsid antigen (anti-VCA), EBV early antigen D (EA-D), and EBV early antigen R (EA-R) were measured by indirect immunofluorescence assays according to Henle et al. I4 Antibodies to EBV nuclear antigens (EBNA) were measured by anticomplement immunofluorescence using Raji cells based on the procedure by Reedman and Klein, but using modifications previously de~cribed.'~ BJAB, an EBV-negative B-cell line, was used as a negative antigen control.
Scaristical analysis. Familial pairs of HD were studied using two end points: (l) the presence of EBERl in the tumors and (2) elevated EBV serology.
For the analysis of EBERl results, families with pairs of cases tested for in situ hybridization were grouped by concordant positivity and discordant and concordant negativity. To test for excess concordance, we used a simple permutation test," ie, assuming the observed prevalence of positives, the number of pairs, and independence, we calculated the exact conditional probability of the observed number of concordant positives or more. This is the P value of the permutation test for excess concordance.
For the analysis of serologic data, titers from HD cases and UFM were compared with their respective age-and sex-matched controls. Fisher's exact test and conditional logistic regression were used to compare rates of seroprevalence. To compare the geometric mean titer (GMT) of seropositive sera, we used standard unmatched r statistics for testing the difference between two means under the assumption of equal variance. The permutation test was again used to test for excess concordance. All tests were two-tailed.
RESULTS
Sixty FHD cases from 27 families were identified for this study (Tables I and 2 ). Most of the 27 kindreds had 2 cases of HD; however, 4 kindreds had 3 cases, and 1 kindred had 4 cases. Sixteen families presented as sibling pairs, 8 as parent-child pairs or parent-children combinations (trios), 1 as first cousin pairs, and 2 as siblings with a cousin or a niece. The male to female ratio was 1 (28 males and 32 females). Age at diagnosis (n = 60) ranged from 11 to 57 years (mean, 28 years; median, 26 years) and 80% were 5 to 40 years of age (Fig 1) ; the mean age at examination and phlebotomy (n = 39) was 32 (median, 31).
UFM were slightly older at the time of examination and phlebotomy, ranging from 10 to 69 years of age (mean, 40 years; median, 39 years). Half were siblings of FHD cases; the other half were their parents. The male to female ratio was approximately the same in both patient and control groups.
Histologic subtypes and positivity for EBER 1. The majority, or 72% (43 of 60), of FHD cases were histologically classified as nodular sclerosis, and 18% (1 1 of 60) as mixed cellularity (Tables 2 and 3 ). Among 46 cases with available tissue blocks for EBV in situ hybridization testing, 83% were nodular-sclerosing, 11% were mixed-cellularity, 4% were lymphocyte-depleted, and 2% were lymphocyte-predominant HD. Among the 14 in which tissue blocks were no longer available, seven cases were mixed-cellularity or lymphocyte-predominant HD. Thirteen of 46 cases (28%) harbored EBERl in the Reed-Stemberg cells. Within each histologic subtype, EBER 1 was detected in 21% (8 of 38) of nodular-sclerosing, 60% (3 of 5 ) of mixed-cellularity, and 100% (2 of 2) of lymphocyte-depleted cases, but was not detected in the single lymphocyte-predominant case. Thirtynine percent (5 of 13) of EBER1-positive cases and 6% (2 of 33) of EBER1-negative cases were classified as mixed cellularity or lymphocyte depletion.
When analyzed by age at diagnosis (Fig l) , 30% (3 of 10) of those who were 11 to 20 years old had EBV-positive tumors, compared with 20% (6 of 31) of those 21 to 30 years old. Ninety-one percent (32 of 46) of the FHD cases were younger than 40 years old at diagnosis, and most of them, or 76% (32 of 42), were EBV-genome-negative in the tumors. Although the numbers were small, the data suggest that those older than 40 years at diagnosis have a higher rate of EBV-positive tumors, or 75% (3 of 4) ( P = .06), compared with all other age subgroups.
Concordance for EBERl positivity. Thirty-four of 46 cases occurred as pairs in 17 families (Table 2) . Of those 17 pairs, only two pairs were concordant for EBERl positivity, four were discordant, and 11 were concordant for EBERl negativity. Given 17 pairs and eight positives, the conditional probability of two or more concordant positives at random is .18, ie, there was not a significant excess of concordant positivity.
EBVserology. As a group, FHD cases had a higher seroprevalence than their corresponding controls and UFM (Table 4). FHD cases had GMTs for VCA-G and EA-D that were significantly greater than their matched controls, which was not age-dependent. The GMTs of VCA-G and EA-D from FHD cases age 15 to 39 years were also significantly higher than their age-matched controls (P = .013 and .029, respectively). Although overall there was no difference in the GMT of EA-D for UFM in comparison to their controls, in the subgroup age 15 to 39 years, the EA-D was signifi- For personal use only. on November 11, 2017. by guest www.bloodjournal.org From Since most people are positive for EBV before the teens, EBNA and VCA-G titers were evaluated for high titer. defined as greater than 1540 and 1:2,560. respectively (90th percentile level for population controls). There were I 5 pairs of first-degree related FHD cases with available serology tests ( Table S) . Two of those pairs demonstrated concordant high titer of EBNA (P = .06) and two demonstrated high titer of VCA-
One of these pairs from one family has elevated titers of both EBNA and VCA-G. There were two pairs that were concordant for positive titer of EA-D (P = .23) and there were no concordant pairs for positive titer of EA-R.
EA-D.

DISCUSSION
These data provide three complementary aspects in the investigation of the relationship of EBV to FHD. Similar to previous studies, patients with FHD have higher seroprevalence and higher antibody titers to EBV compared with either UFM or general population controls. As in case series of HD. the familial patients with mixed-cellularity or lymphocytedepleted HD are more likely to have EBV detected in the tumors by in situ hybridization than those with nodularsclerosing HD. In addition, the age associations with EBV in situ positivity are similar to those described in other popu- lations. However, the unique contribution of evaluating this group of patients is the examination of concordance within each family. If EBV were a shared environmental exposure important in the development of HD, one might expect to see high concordance rates, but we did not. Previous seroepidemiologic studies have examined either cohort^'^.'' or siblingstx as control groups for comparison of EBV titers. We used both first-degree relative controls and age-matched general population controls. Unaffected relatives of the HD patients had higher titers for EA-D than the population controls in the young adult age groups. The data suggest that family members from FHD may not be similar to the general population in exposure or reaction to EBV. The HD patients had higher titers for VCA-G and EA-D than either control group. These data are consistent with previously published findings, and indicate that other factors may be important in developing HD. The in situ hybridization assay appears to be the most specific method to evaluate the association of EBV with HD."' Overall. 28% (95% confidence interval, 0.15 to 0.41) of the evaluated cases were found to have the EBV genome in the tumor tissue. This is within previously reported ranges of EBV positivity. The relatively lower rate of positivity is not unexpected because of the histologic distribution of these cases.2'' the young adult age of onset," and the high socioeconomic status of these families.' It is noteworthy that the two families concordant for EBV positivity by in situ hybridization were not the same families that demonstrated concordance for high serologic titers. These and other data" suggest that there is a discrepancy between EBV titers and the presence of EBV genome in the Reed-Sternberg cells. One possible explanation of the discrepancy is that, on average, these cases underwent phlebotomy about 4 years after diagnosis of HD (Table l) . The titers at the time of diagnosis of HD may have differed.
There are several sources of potential bias that may contribute to the lack of concordance in EBV by in situ hybridization or serology in this study. First, of 14 cases with no pathology blocks available, almost half were mixed-cellularity or lymphocyte-depleted HD, which are more likely to be EBV-positive. Of the 14, only five (two mixed cellularity, two nodular sclerosis, and one unknown type) occurred in families in which there was no EBV-positive HD. There are, therefore, missing data that could potentially affect the concordance rates found. To evaluate the effect of the missing data, we assumed that a missing case in each family was EBV positive to maximize the effect. Even in this extreme example, we would then have seven concordant positive pairs, eight discordant. and 1 I concordant negative. The outFor personal use only. on November 11, 2017. by guest www.bloodjournal.org From come being random could not be excluded (P > .05), and the data still would not be consistent with EBV playing a major role in FWD in these families.
Another limitation of using concordance rates as a measure of the importance of EBV infection is that concordance may be too crude a measure of gene-environment interaction. EBV could be important in a subset of FHD with a specific genetic predisposition that is not yet identified. However, data from a recent twin study, suggest that this may not account for the majority of FHD. Mack et alZ3 found that one of 10 monozygotic twin pairs was concordant for EBV genome by in situ hybridization. However, the twin data suggest that susceptibility genes are important in the development of young adult HD. Hospital-based case-control studies and population-based surveys have found that 0.3% to 4.9% of newly diagnosed patients with HD report a positive family history of HD.24-26 There is no clear-cut mendelian transmission pattern in reported families, but where it has been evaluated, it appears that FHD is genetically heterogeneous. A subset of the families may have a HD susceptibility gene linked to the HLA r e g i~n .~ When appropriate candidate genes have been identified and isolated, it may be Further studies are required to define the role of EBV in EBV-positive cases, identify other factors in EBV-negative cases, and/or disentangle a gene-environmental interaction. Studies in high-risk cancer families, such as hereditary breast-ovarian cancer, or rare cancer family syndromes, such as Li-Fraumeni syndrome, which arise from inherited susceptibility to cancer, frequently result in identification of crucial gene(s). Given the rarity of FHD, continuing effort to collect more cases and perform a larger scale study, such as an international collaboration, could potentially lead to the understanding of its genetic basis. For personal use only. on November 11, 2017. by guest www.bloodjournal.org From
